HRTX vs. NVDA

Last updated Apr 1, 2026

Compare and contrast key facts about Heron Therapeutics, Inc. (HRTX) and NVIDIA Corporation (NVDA).

Performance

HRTX vs. NVDA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Heron Therapeutics, Inc. (HRTX) and NVIDIA Corporation (NVDA). The values are adjusted to include any dividend payments, if applicable.

HRTX vs. NVDA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
HRTX Heron Therapeutics, Inc.	-38.45%	-15.03%	-10.00%	-32.00%	-72.62%	-56.86%	-9.94%	-9.41%	43.31%	38.17%
NVDA NVIDIA Corporation	-6.48%	38.92%	171.25%	239.02%	-50.26%	125.48%	122.30%	76.94%	-30.82%	81.99%

Fundamentals

Market Cap HRTX : $133.38M NVDA : $4.26T
EPS HRTX : -$0.12 NVDA : $4.90
PS Ratio HRTX : 0.85 NVDA : 19.80
PB Ratio HRTX : 10.04 NVDA : 27.09
Total Revenue (TTM) HRTX : $154.90M NVDA : $215.94B
Gross Profit (TTM) HRTX : $113.56M NVDA : $153.46B
EBITDA (TTM) HRTX : -$10.10M NVDA : $144.55B

Returns By Period

In the year-to-date period, HRTX achieves a -38.45% return, which is significantly lower than NVDA's -6.48% return. Over the past 10 years, HRTX has underperformed NVDA with an annualized return of -27.84%, while NVDA has yielded a comparatively higher 69.61% annualized return.

HRTX

• 1D: 7.27%
• 1M: -32.76%
• YTD: -38.45%
• 6M: -36.50%
• 1Y: -63.63%
• 3Y*: -19.08%
• 5Y*: -45.47%
• 10Y*: -27.84%

NVDA

• 1D: 5.59%
• 1M: -1.57%
• YTD: -6.48%
• 6M: -6.52%
• 1Y: 60.95%
• 3Y*: 84.54%
• 5Y*: 66.14%
• 10Y*: 69.61%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

HRTX vs. NVDA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

HRTX

HRTX Risk / Return Rank: 6
HRTX Sharpe Ratio Rank: 5
HRTX Sortino Ratio Rank: 5
HRTX Omega Ratio Rank: 6
HRTX Calmar Ratio Rank: 6
HRTX Martin Ratio Rank: 8

NVDA

NVDA Risk / Return Rank: 83
NVDA Sharpe Ratio Rank: 85
NVDA Sortino Ratio Rank: 82
NVDA Omega Ratio Rank: 80
NVDA Calmar Ratio Rank: 86
NVDA Martin Ratio Rank: 85

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

HRTX vs. NVDA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Heron Therapeutics, Inc. (HRTX) and NVIDIA Corporation (NVDA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	HRTX	NVDA	Difference
Sharpe ratio Return per unit of total volatility	-0.98	1.48	-2.46
Sortino ratio Return per unit of downside risk	-1.58	2.17	-3.75
Omega ratio Gain probability vs. loss probability	0.81	1.27	-0.47
Calmar ratio Return relative to maximum drawdown	-0.93	2.92	-3.86
Martin ratio Return relative to average drawdown	-1.56	7.39	-8.95
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

HRTX vs. NVDA - Sharpe Ratio Comparison

The current HRTX Sharpe Ratio is -0.98, which is lower than the NVDA Sharpe Ratio of 1.48. The chart below compares the historical Sharpe Ratios of HRTX and NVDA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	HRTX	NVDA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.98	1.48	-2.46
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.52	1.29	-1.81
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.37	1.40	-1.78
Sharpe Ratio (All Time) Calculated using the full available price history	-0.20	0.61	-0.81

Correlation

The correlation between HRTX and NVDA is 0.15, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

HRTX vs. NVDA - Dividend Comparison

HRTX has not paid dividends to shareholders, while NVDA's dividend yield for the trailing twelve months is around 0.02%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
HRTX Heron Therapeutics, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NVDA NVIDIA Corporation	0.02%	0.02%	0.03%	0.03%	0.11%	0.05%	0.12%	0.27%	0.46%	0.29%	0.45%	1.20%

Drawdowns

HRTX vs. NVDA - Drawdown Comparison

The maximum HRTX drawdown since its inception was -99.96%, which is greater than NVDA's maximum drawdown of -89.72%. Use the drawdown chart below to compare losses from any high point for HRTX and NVDA.

Drawdown Indicators

	HRTX	NVDA	Difference
Max Drawdown Largest peak-to-trough decline	-99.96%	-89.72%	-10.24%
Max Drawdown (1Y) Largest decline over 1 year	-69.18%	-20.21%	-48.97%
Max Drawdown (5Y) Largest decline over 5 years	-97.08%	-66.34%	-30.74%
Max Drawdown (10Y) Largest decline over 10 years	-98.71%	-66.34%	-32.37%
Current Drawdown Current decline from peak	-99.94%	-15.76%	-84.18%
Average Drawdown Average peak-to-trough decline	-81.58%	-36.40%	-45.18%
Ulcer Index Depth and duration of drawdowns from previous peaks	41.31%	7.99%	+33.32%

Volatility

HRTX vs. NVDA - Volatility Comparison

Heron Therapeutics, Inc. (HRTX) has a higher volatility of 19.13% compared to NVIDIA Corporation (NVDA) at 10.46%. This indicates that HRTX's price experiences larger fluctuations and is considered to be riskier than NVDA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	HRTX	NVDA	Difference
Volatility (1M) Calculated over the trailing 1-month period	19.13%	10.46%	+8.67%
Volatility (6M) Calculated over the trailing 6-month period	40.77%	25.91%	+14.86%
Volatility (1Y) Calculated over the trailing 1-year period	65.09%	41.44%	+23.65%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	87.85%	51.74%	+36.11%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	74.47%	49.85%	+24.62%

Financials

HRTX vs. NVDA - Profitability Comparison

The chart below illustrates the profitability comparison between Heron Therapeutics, Inc. and NVIDIA Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

HRTX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Heron Therapeutics, Inc. reported a gross profit of 32.94M and revenue of 40.59M. Therefore, the gross margin over that period was 81.2%.

NVDA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, NVIDIA Corporation reported a gross profit of 51.09B and revenue of 68.13B. Therefore, the gross margin over that period was 75.0%.

HRTX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Heron Therapeutics, Inc. reported an operating income of 38.00K and revenue of 40.59M, resulting in an operating margin of 0.1%.

NVDA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, NVIDIA Corporation reported an operating income of 44.30B and revenue of 68.13B, resulting in an operating margin of 65.0%.

HRTX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Heron Therapeutics, Inc. reported a net income of -2.95M and revenue of 40.59M, resulting in a net margin of -7.3%.

NVDA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, NVIDIA Corporation reported a net income of 42.96B and revenue of 68.13B, resulting in a net margin of 63.1%.